Traynelis, S
Rybelsus (semaglutide) is indeed a GLP-1 receptor agonist, specifically the first and only oral formulation of this medication class approved for type 2 diabetes management
doi: 10.1016/S0006-2952(02)01172-3
It likely reflect the microbes they have in their gut. But ultimately, he says, while short-term studies looking at the impact of fibers on short chain fatty acid production or the second meal effect* are valuable, the only real test of whether these ingredients amount to Natures Ozempic is looking at clinical endpoints, whether its weight loss, or insulin sensitivity, for example. *the ability of a food to impact consumption at a subsequent meal later in the day or the following day
CEO Lee stated, D&D Pharmatech continues platform-based clinical expansion across two pillars: liver disease and CNS. He added, Histological results and additional biomarker data for DD01 will be released in the second quarter of this year. During the Q&A session after the presentation, a question was raised about DD01's strategic positioning, given that recently approved GLP-1 agonists for obesity treatment, such as Wegovy and Mounjaro, are now expanding into MASH indications
Temporelli PL
